Metoclopramidemonohydrochloride Accord

Metoclopramide Hydrochloride, the active ingredient in Metoclopramidemonohydrochloride Accord, is a dopamine antagonist presented as an oral tablet for oral use. It is used to treat nausea, vomiting, gastroparesis, gastro‑oesophageal reflux disease and pre‑ or post‑operative nausea in adult patients.

GNH USA supplies Metoclopramidemonohydrochloride Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metoclopramide acts on the dopaminergic and serotonergic pathways to control nausea, vomiting and gastrointestinal motility.

- Nausea and vomiting: reduces frequency and severity of acute and chemotherapy‑induced episodes. - Gastroparesis: enhances gastric emptying and relieves associated symptoms. - Gastro‑oesophageal reflux disease (GERD): decreases reflux episodes by improving lower esophageal sphincter tone. - Pre‑operative and post‑operative nausea: prevents and treats nausea related to surgical procedures.

Metoclopramide may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Drowsiness: feeling unusually sleepy or fatigued. - Restlessness: inability to stay still or calm. - Diarrhea: loose or frequent stools. - Headache: mild to moderate head pain. - Dizziness: sensation of light‑headedness or vertigo. - Fatigue: overall lack of energy.

Serious or Rare Side Effects: - Extrapyramidal symptoms: involuntary muscle movements or rigidity. - Tardive dyskinesia: persistent, irreversible facial or tongue movements. - Neuroleptic malignant syndrome: life‑threatening fever and muscle rigidity. - Depression or suicidal thoughts: mood changes requiring immediate attention. - Cardiac arrhythmia: irregular heart rhythm. - Hyperprolactinemia: elevated prolactin levels causing hormonal effects.

Before prescribing Metoclopramide, clinicians should consider several safety factors.

- Pregnancy: Category B – use only if potential benefit justifies the potential risk to the fetus. - Renal impairment: dose adjustment may be required in patients with reduced kidney function. - History of movement disorders: avoid in patients with Parkinson's disease or tardive dyskinesia. - Concomitant CNS depressants: monitor for enhanced sedation or respiratory depression. - Store at ambient temperature: keep below 25 °C, retain in original packaging, and protect from moisture.

Metoclopramide can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Anticholinergic agents: may reduce pro‑kinetic effect. - CNS depressants (e.g., benzodiazepines): increased sedation risk. - MAO inhibitors: heightened risk of hypertensive crisis. - CYP2D6 inhibitors: elevated plasma levels of metoclopramide. - QT‑prolonging drugs: additive risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - Opioids: may enhance nausea control but increase sedation. - Antihistamines: possible additive drowsiness. - SSRIs: monitor for serotonin syndrome. - Diabetic medications: may affect glucose control. - Alcohol: increased central nervous system effects.